Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Intratumoural Interleukin-2 Therapy Can Induce Regression of Non-resectable Mastocytoma in Dogs

PAUL G.P.M. ZIEKMAN, WILLEM DEN OTTER, JURGEN F.V. TAN, ERIK TESKE, JOLLE KIRPENSTEIJN, JAN-WILLEM KOTEN and JOHN J.L. JACOBS
Anticancer Research January 2013, 33 (1) 161-165;
PAUL G.P.M. ZIEKMAN
1Department of Urology, VU University Medical Centre, Amsterdam, the Netherlands
2Veterinary Clinic Oisterwijk, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WILLEM DEN OTTER
1Department of Urology, VU University Medical Centre, Amsterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: W.den.Otter@live.nl
JURGEN F.V. TAN
1Department of Urology, VU University Medical Centre, Amsterdam, the Netherlands
3Veterinary Clinic De Korte Akkeren, Gouda, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ERIK TESKE
4Department of Clinical Sciences of Companion Animals, Utrecht University, Utrecht, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOLLE KIRPENSTEIJN
4Department of Clinical Sciences of Companion Animals, Utrecht University, Utrecht, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JAN-WILLEM KOTEN
1Department of Urology, VU University Medical Centre, Amsterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOHN J.L. JACOBS
1Department of Urology, VU University Medical Centre, Amsterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: Mast cell tumours (MCT) are common skin tumours in dogs. If complete surgical removal of the tumours is not possible, then another therapy is needed. In the current study we tested the therapeutic effect of intratumoural injection of interleukin-2 (IL-2). Materials and Methods: Seven dogs had non-resectable cutaneous MCT. The tumours were injected with 4.5×106 IU IL-2. Results: The early clinical effects in the seven dogs with cutaneous MCT were: complete regression (CR) in two dogs; partial regression (PR) in four, and stable disease (SD) in one dog. The final clinical effects were CR in three dogs, PR in two dogs, and PD in two dogs. Conclusion: This pilot study shows that intratumoural IL-2 application can exert an anti-MCT effect. A larger study would be required to precisely establish the magnitude of the therapeutic effect against MCT. A single application of IL-2 in cases of non-resectable MCT has no observable side-effects.

  • Mastocytoma
  • interleukin-2
  • local therapy
  • immunotherapy
  • dogs

Mastocytomas (MCT) are common tumours of the skin in dogs (1). MCTs represent 6% of all tumours in the dog and 13% of all skin tumours in the dog (2). The mean age of dogs with cutaneous MCT is approximately 9 years. The biological behaviour of MCTs is variable; some dogs have solitary tumours, while others have multiple tumours (3). Surgical removal of MCTs is the treatment of choice. Wide margins (2 to 3 cm) are required because of the tendency of the tumour cells to spread around the tumour (4, 5). If complete removal with margins is not possible due to the size or location, additional treatment such as radiotherapy or chemotherapy may be necessary (6, 7).

IL-2 is a cytokine that has antitumour effects when given systemically to human patients (8, 9, 10). The disadvantage of systemic IL-2 therapy is that the therapeutic effect is limited to about 20% objective responses in patients with metastasized renal cell carcinoma and metastasized melanoma (9). In addition, systemically-applied IL-2 causes severe side effects due to the generalized vascular leakage syndrome (9, 11, 12).

Local IL-2 application (intratumoural, peritumoural, intravesical) is far more effective than systemic IL-2 therapy. Locally-applied IL-2 causes hardly any side-effects (13-18). Our group is specialised in cancer treatment by local application of IL-2 (16). We have obtained good therapeutic effects against cancer in veterinary patients such as bovine ocular squamous cell carcinoma (19-21), bovine vulval papilloma and carcinoma complex (22, 23) and sarcoids in horses (24). In human patients, we have shown that local IL-2 application is therapeutically-effective against superficial bladder carcinoma (25) and nasopharyngeal carcinoma (15). The groups of Radny (14) and Pfohler (26) showed the effect of local IL-2 application on melanoma. IL-2 is also effective in a variety of other cancer types (10, 16).

Local injection of IL-2 leads to extravasation of fluid and erythrocytes at the injection site (11, 12, 27). This causes stagnation of the blood flow, leading to tumour cell death. At a later stage, leucocytes migrate to the dead tumour cells; this stimulates the immune response (16, 28, 29). In this article we describe a pilot study on the therapeutic effects of intratumoural application of IL-2 in dogs with non-resectable MCT.

Materials and Methods

Dogs with cutaneous MCTs were presented at our clinics in Oisterwijk and in Gouda. Inclusion criteria for this study were: (a) Cytologically-confirmed MCT that was thought to be non-resectable; tumours were regarded to be non-resectable when surgery required amputation that was not acceptable to the owner. Animals with metastasis were accepted. (b) Clinical performance 0 (no clinical signs) to 3 (some tiredness and dyspnea). Exclusion criteria were: (a) Dogs that were thought to have surgically-resectable MCT. (b) The presence of other types of tumor. (c) Clinical performance 4 or 5 (poor condition: not able to care for themselves or close to death). (d) Previous treatments. All patients presented to our clinics fulfilling these criteria were included. The WHO or Zubrod clinical performance scale was used (30). Staging of the MCT was not performed as the group of 10 dogs was regarded to be too small for statistical analysis of subgroups. Urine analysis was not performed. H1/H2 antagonists were not needed and were not used. We performed an abdominal ultrasound search for metastases, especially in the liver and the spleen. Metastasis was confirmed cytologically.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Dogs with cytologically-proven mast cell tumours.

Tumours in 10 dogs were unresectable and these were treated with intratumoural IL-2 therapy only. Three of these dogs had metastases: two of them had metastasis in the regional lymph node and one had a local metastasis (new tumour around the primary tumour) in the skin. The animals received one injection of 4.5×106 units of human recombinant IL-2 (Proleukin®, Novartis, Arnhem) in 0.25 ml solution in the primary tumour. This dose and the volume of the suspension were based on results described by Den Otter et al. (16). Only one injection of IL-2 was given, as experience has shown that one dose is usually effective (16). An exception was described by Kusnierczyk and others (31), but in their study in mice, additional IL-2 injections were given when the tumour started to re-grow; of course we could not do this for logistic reasons. Patients with a primary skin tumour and metastasis were included because in several studies it was shown that treatment of the primary tumour with IL-2 could lead to the regression of a metastasis (13, 29, 32).

Dogs were examined every month. Special attention was paid to the tumour size and the regional lymph nodes. Therapeutic effects are expressed as complete regression (CR): no tumour visible, partial regression (PR): tumour size less than 50% of the original tumour), stable disease (SD): tumour size 50-150% of the original tumour, and progressive disease (PD): tumour size more than 150% of the original tumour or tumour growth leading to death. Dogs were euthanized when they were too ill. We distinguished early and final clinical effects. Early effects are effects measured during the first seven months after treatment. Final clinical effects are effects at the last visit of the living animal (before death due to cancer or other causes, or due to exclusion from further analysis).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Location of the skin tumours

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Therapeutic results of intratumoural IL-2 therapy.

Ethics. This research was performed in compliance with the guidelines of the Department of Clinical Sciences of Companion Animals, Utrecht. Written informed consent to treat the animals was given by the owners of the dogs.

Results

Ten dogs with non-resectable MCTs were treated with IL-2 injections into the primary tumour. Tables I and II present information about these dogs and their tumours. The age of the dogs was 3.5 to 14 years, with a mean of 8.8 years. The longest diameter of the tumours ranged from 10 to 65 mm (median=32 mm).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Growth kinetics of skin tumours after local IL-2 therapy-only. Closed symbols are data from animals with metastases. Open symbols are data from animals without metastases; Six out of seven cases of primary tumours without metastases regressed. Skin tumours with metastases tended to grow. Tumour regression is often a slow process, requiring more than 6 months.

We did not observe any side-effects of local IL-2 treatment of MCT; thus no supplementary medication was required.

Non-metastasized tumours. Seven dogs had locally advanced tumours only (D1–D7; Tables I and II). Therapeutic effects are shown in Table III and Figure 1. Local treatment of mastocytomas D1–D7 led to clear early clinical effects: 2 CRs, 4 PRs, and 1 SD. The CRs lasted for 21 months (D5) and 6 months (D6). The final clinical effect observed at 5-29 months after treatment was 3 CRs, 2 PRs, and 2 PD. Consequently, in 5/7 animals there was a worthwhile clinical effect. Figure 1 shows that tumour regression induced by intratumoural IL-2 may be a slow process; regression of 4/5 tumours required more than 6 months. In one of the dogs with a PR (D2), the tumour became surgically removable. Therefore this dog was excluded from further analysis.

Metastasized tumours. Dog M1 had a metastasis in the regional lymph node. The primary tumour showed SD from 7 months to 10 months after treatment. Thereafter tumour growth progressed leading to death of the dog.

Dog M2 had a skin metastasis near the primary tumour. This dog died 2 months after treatment due to the tumour, without noticeable change of the size of the primary tumour, but the metastasis was growing.

Dog M3 had a metastasis in the regional lymph node. The primary tumour did not change in size after IL-2 treatment of the primary tumour up to 5 months after treatment. Only after 35 months' tumour progression did this dog die from MCT.

In dogs M1–M3 their metastases did not regress after IL-2 application to the primary tumour.

Figure 1 shows the different therapeutic effects in animals with non-metastasised skin tumours and those with primary tumours with a metastasis: those with non-metastasised tumours usually showed a therapeutic effect (CR, PR, SD), whereas the primary tumours with a metastasis did not regress.

Discussion

In this article we describe local (intratumoural) IL-2 application for non-resectable MCT in dogs. The therapeutic effect against inoperable, non-metastasized MCT is convincing: two dogs (numbers D5 and D6) had a CR. In D5, this lasted for at least 21 months. Three dogs (D1–D3) had a PR with a 4- to 7-fold decrease in tumour size. The tumour in dog 2 regressed sufficiently for surgery to be undertaken. A longer follow-up might have resulted in even better results, as the tumour response to IL-2 is often slow. Such a slow regression has also been reported in cattle with ocular squamous cell carcinoma treated with local IL-2 therapy (19-21). Slow tumour regression is also the case in MCT, as illustrated in Figure 1, where the regression of tumours of four dogs required more than six months.

In the three dogs with metastasized MCTs no therapeutic effects were obtained, as early effects comprised of two SDs and one PD, and the final clinical effects were three PDs. The lack of effect on the non-treated metastases was rather surprising as in other models there were therapeutic effects on non-treated tumours at a distant site. This occurred with transplanted SL2 lymphoma in mice (13, 29, 32), transplanted carcinoma in the ears of rabbits (33) and bovine vulval papilloma and carcinoma complex (22).

We explain the mechanism of local IL-2 activity as follows: IL-2 induces vascular leakage leading to oedema. This inhibits the circulation of fluid, causing lack of oxygen and nutrients for the tumour cells. Many of these tumour cells die. The tumour debris is phagocytosed and this leads to immunity (16). This immune process and in particular the phagocytic process, requires time. This explains why tumour regression requires months.

Local IL-2 treatment of MCT in dogs is easy. We did not observe any side-effect of local IL-2 treatment of MCT (erythema, necrosis, pain, gastrointestinal effects, etc.). Den Otter et al. (16) reviewed the toxic effects of local IL-2 application to human patients with cancer. There were 24 articles with an abstract mentioning toxic side-effects. In 20, there were no or only minor side effects reported, one reported some side-effects (1/9 patients had fever grade I and 7/9 patients had hypotension grade I-II) and 3 mentioned more serious side-effects. The latter three studies used very high doses for intrapleural, intraperitoneal or subcutaneous administration. Hence, side effects are mainly expected after very high doses of IL-2, but not after the relatively low doses that we applied locally. Such massive doses act in a pseudo-systemic manner. Much of the IL-2 is absorbed and as a consequence will give generalised effects similar to systemic treatment.

Usually it is not necessary to sedate the animal. Only a single treatment is sufficient in most cases (16, 33). A clear exception was the treatment of transplanted MC38 colon carcinoma in mice, where multiple IL-2 treatments led to better therapeutical effects than did a single treatment (31).

The results described here warrant further studies on local IL-2 application for MCT in dogs. These studies should comprise of more animals than we included, compare therapeutic effects after single and multiple local IL-2 applications, and should use stratification to allow for comparison of the therapeutic effects on MCTs with different grades of malignancy. The effects on non-treated metastases also requires further study.

Conclusion

A single application of IL-2 for non-resectable MCT is feasible, has no observable side- effects, does not require invasive surgery, does not need frequent irradiation sessions with sedation, does not need multiple toxic chemotherapy, and is cheap. This study shows convincingly that local IL-2 application can exert a therapeutic effect against MCT. The results warrant a larger study with more patients to establish the anti-MCT effect more precisely.

Acknowledgements

We acknowledge receiving a grant of the Stichting Nationaal Fonds tegen Kanker (SNFK), Amsterdam, to JJLJ

Footnotes

  • This article is freely accessible online.

  • Conflicts of Interest

    None of the Authors of this article has financial or personal relationship with other people or organisations that could inappropriately influence or bias the content of the article.

  • Received October 4, 2012.
  • Revision received November 23, 2012.
  • Accepted November 26, 2012.
  • Copyright© 2013 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. 1.↵
    1. Priester WA
    : Skin tumors in domestic animals. Data from 12 United States and Canada colleges of veterinary medicine. J Nat Cancer Inst 50: 457-466, 1973.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Orkin M,
    2. Schwarzman RM
    : Comparative study of canine and human dermatology. II. Cutaneous tumors: The mast cell and canine mastocytoma. J Investigative Dermatol 32: 451-466, 1959.
    OpenUrlPubMed
  3. 3.↵
    1. Withrow SJ,
    2. EG MacEwen EG
    1. Vail DM
    : Mast cell tumors. In: Small Animal Clinical Oncology; Withrow SJ, EG MacEwen EG (eds.). W.B. Saunders, London, p. 192, 1989.
  4. 4.↵
    1. Dobson J,
    2. Lascelles B,
    3. Duncan X
    1. Murphy S
    : Mast cell tumours. In: BSAVA Manual of Canine and Feline Oncology. Dobson J, Lascelles B, Duncan X (eds.). John Wiley & Sons, London, pp. 161-167, 2003.
  5. 5.↵
    1. Simpson AM,
    2. Ludwig LL,
    3. Newman SJ,
    4. Bergman PJ,
    5. Hottinger HA,
    6. Patnaik AK
    : Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. J Vet Med Assoc 224: 236-240, 2004.
    OpenUrl
  6. 6.↵
    1. Bostock DE
    : The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract 14: 27-41, 1973.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Michels GM,
    2. Knapp DW,
    3. DeNicola DB,
    4. Glickman N,
    5. Bonney P
    : Prognosis following surgical excision of canine cutaneous mast cell tumors with histopatologically tumor-free versus nontumor-free margins. J Am Anim Hosp Assoc 38: 458-466, 2002.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Rosenberg SA,
    2. Lotze MT,
    3. Muul LM,
    4. Leitman S,
    5. Chang AE,
    6. Ettinghausen SE,
    7. Matory YL,
    8. Skibber JM,
    9. Shiloni E,
    10. Vetto JT
    : Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant IL-2 to patients with metastatic cancer. New Engl J Med 313: 1485-1492, 1985.
    OpenUrlPubMed
  9. 9.↵
    1. Janssen RA,
    2. Mulder NH,
    3. The TH,
    4. De Leij L
    : The immunological effects of interleukin-2 in vivo. Cancer Immunol Immunother 39: 207-216, 1994.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Grande C,
    2. Firvida JL,
    3. Navas V,
    4. Casal J
    : Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs 17: 1-12, 2006.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Rosenstein M,
    2. Ettinghausen SE,
    3. Rosenberg SA
    : Extravasation of extravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137: 1735-1742, 1986.
    OpenUrlAbstract
  12. 12.↵
    1. Baluna R,
    2. Vitetta E
    : Vascular leak syndrome: A side-effect of immunotherapy. Immunopharmacol 37: 117-132, 1997.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Maas RA,
    2. Dullens HFJ,
    3. De Jong WH,
    4. Den Otter W
    : Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin-2. Cancer Res 49: 7037-7040, 1989.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Radny P,
    2. Caroli UM,
    3. Bauer J,
    4. Paul T,
    5. Schlegel C,
    6. Eigentler TK,
    7. Weide B,
    8. Schwartz M,
    9. Garbe C
    : Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89: 1620-1626, 2003.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Jacobs JJL,
    2. Hordijk GJ,
    3. Jűrgenliemk-Schulz IM,
    4. Terhaard CH,
    5. Koten JW,
    6. Battermann JJ,
    7. Den Otter W
    : Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2. Cancer Immunol Immunother 54: 792-798, 2005.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Den Otter W,
    2. Jacobs JJL,
    3. Battermann JJ,
    4. Hordijk G,
    5. Krastev Z,
    6. Moiseeva EV,
    7. Stewart RJ,
    8. Ziekman PGP,
    9. Koten JW
    : Local therapy of cancer with free IL-2. Cancer Immunol Immunother 57: 931-950, 2008.
    OpenUrlCrossRefPubMed
  17. 17.
    1. Shaker MA,
    2. Younes HM
    : Interleukin-2: Evaluation of routes of administration and current delivery systems in cancer therapy. J Pharmacol Sciences 98: 2268-2298: 2009.
    OpenUrl
  18. 18.↵
    1. Stewart RJ,
    2. Masztalerz A,
    3. Jacobs JJ,
    4. Den Otter W
    : Local interleukin-2 and interleukin-12 therapy of bovine ocular squamous cell carcinomas. Vet Immunol Immunopathol 106: 277-284, 2005.
    OpenUrlPubMed
  19. 19.↵
    1. Rutten VPMG,
    2. Klein WR,
    3. De Jong WA,
    4. Misdorp W,
    5. Den Otter W,
    6. Steerenberg PA,
    7. De Jong WH,
    8. Ruitenberg EJ
    : Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study. Cancer Immunol Immunother 30: 165-169, 1989.
    OpenUrlPubMed
  20. 20.
    1. Den Otter W,
    2. Hill FWG,
    3. Klein WR,
    4. Koten JW,
    5. Steerenberg PA,
    6. De Mulder PH,
    7. Rhode C,
    8. Stewart R,
    9. Faber JA,
    10. Ruitenberg EJ,
    11. Rutten VPMG
    : Therapy of bovine ocular squamous cell carcinoma with local doses of interleukin-2: 67% complete regression after 20 months of follow-up. Cancer Immunol Immunother 41: 10-14, 1995.
    OpenUrlPubMed
  21. 21.↵
    1. Stewart RJE,
    2. Hill FW,
    3. Masztalerz A,
    4. Jacobs JJL,
    5. Koten JW,
    6. Den Otter W
    : Treatment of ocular squamous cell carcinomas in cattle with interleukin-2. Vet Rec 159: 668-672, 2006.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Hill FWG,
    2. Klein WR,
    3. Hoyer HJ,
    4. Rutten VPMG,
    5. Kock N,
    6. Koten JW,
    7. Steerenberg PA,
    8. Ruitenberg EJ,
    9. Den Otter W
    : Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma. Vet Immunol Imunopathol 41: 19-29, 1994.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Stewart RJE,
    2. Jacobs JJL,
    3. Koten JW
    : Local interleukin-2 therapy of bovine vulval papilloma and carcinoma complex. Vet Rec 167: 825-826, 2010.
    OpenUrlFREE Full Text
  24. 24.↵
    1. Spoormakers TJ,
    2. Klein WR,
    3. Jacobs JJL,
    4. Van Den Ingh TS,
    5. Kotem JW,
    6. Den Otter W
    : Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2. Cancer Immunol Immunother 52: 179-184, 2003.
    OpenUrlPubMed
  25. 25.↵
    1. Den Otter W,
    2. Dobrowolski Z,
    3. Bugajski A,
    4. Papla B,
    5. Van der Meijden AP,
    6. Koten JW,
    7. Boon TA,
    8. Siedlar M,
    9. Zembala M
    : Intravesical IL-2 to treat T1 papillary carcinoma: Regression of marker lesions in 8 out of 10 patients. J Urol 159: 1183-1186, 1998.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Pfohler C,
    2. Steinhauser S,
    3. Wagner A,
    4. Urugel S,
    5. Tilgen W
    : Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in two patients with malignant melanoma (German). Hautarzt 55: 171-175, 2004.
    OpenUrlPubMed
  27. 27.↵
    1. Jacobs JJL,
    2. Sparendam D,
    3. Den Otter W
    : Local interleukin 2 therapy is most effective against cancer when injected intratumorally. Cancer Immunol Immunother 54: 647-654, 2005.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Maas RA,
    2. Roest PA,
    3. Becker M,
    4. Weimar IS,
    5. Dullens HFJ,
    6. Den Otter W
    : Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: Tumor cell killing by CD8+ cytotoxic T-lymphocytes and macrophages. Immunobiol 186: 214-223, 1992.
    OpenUrlPubMed
  29. 29.↵
    1. Maas RA,
    2. Van Weering DHJ,
    3. Dullens HFJ,
    4. Den Otter W
    : Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol Immunother 33: 389-394, 1991.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Oken MM,
    2. Creech RH,
    3. Tormey DC,
    4. Horton J,
    5. Davis TE,
    6. McFadden ET,
    7. Carbone PP
    : Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Kusnierczyk H,
    2. Pajtasz-Piasecka EE,
    3. Koten JW,
    4. Bijleveld C,
    5. Krawczyk K,
    6. Den Otter W
    : Further development of local IL-2 therapy of cancer: Multiple versus single IL-2 treatment of transplanted murine colon carcinoma. Cancer Immunol Immunother 53: 445-452, 2004.
    OpenUrlPubMed
  32. 32.↵
    1. Everse LA,
    2. Renes IB,
    3. Jürgenliemk-Schulz I.M,
    4. Rutgers DH,
    5. Bernsen MR,
    6. Dullens HFJ,
    7. Den Otter W,
    8. Battermann JJ
    : Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study. International J Cancer 72: 1003-1007, 1997.
    OpenUrl
  33. 33.↵
    1. Van Es R,
    2. Baselmans AHC,
    3. Koten JW,
    4. Van Dijk JE,
    5. Koole R,
    6. Den Otter W
    : Perilesional treatment of a VX2 head and neck cancer model can induce a systemic anti-tumor activity. Anticancer Res 20: 4163-4170, 2000.
    OpenUrlPubMed
  34. 33.↵
    1. Den Otter W,
    2. Cadée J,
    3. Gavhumende R,
    4. De Groot CJ,
    5. Hennink WE,
    6. Stewart R
    : Effective cancer therapy with a single injection of interleukin-2 at the site of the tumor. Cancer Immunol Immunother 48: 419-420, 1999.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 33 (1)
Anticancer Research
Vol. 33, Issue 1
January 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Intratumoural Interleukin-2 Therapy Can Induce Regression of Non-resectable Mastocytoma in Dogs
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Intratumoural Interleukin-2 Therapy Can Induce Regression of Non-resectable Mastocytoma in Dogs
PAUL G.P.M. ZIEKMAN, WILLEM DEN OTTER, JURGEN F.V. TAN, ERIK TESKE, JOLLE KIRPENSTEIJN, JAN-WILLEM KOTEN, JOHN J.L. JACOBS
Anticancer Research Jan 2013, 33 (1) 161-165;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Intratumoural Interleukin-2 Therapy Can Induce Regression of Non-resectable Mastocytoma in Dogs
PAUL G.P.M. ZIEKMAN, WILLEM DEN OTTER, JURGEN F.V. TAN, ERIK TESKE, JOLLE KIRPENSTEIJN, JAN-WILLEM KOTEN, JOHN J.L. JACOBS
Anticancer Research Jan 2013, 33 (1) 161-165;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Effective Treatment of Transmissible Venereal Tumors in Dogs with Vincristine and IL2
  • Treatment of Transmissible Venereal Tumors in Dogs with Intratumoral Interleukin-2 (IL-2). A Pilot Study
  • High Expression of Fusion Proteins Consisting of a Single-chain Variable Fragment Antibody Against a Tumor-associated Antigen and Interleukin-2 in Escherichia coli
  • Google Scholar

More in this TOC Section

  • PTPN3 Could Βe a Therapeutic Target of Pancreatic Cancer
  • Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma
  • Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance via Inhibition of RAF Dimerization in PLX4032-resistant Melanoma
Show more Experimental Studies

Similar Articles

Keywords

  • Mastocytoma
  • Interleukin-2
  • local therapy
  • immunotherapy
  • dogs
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire